Logo

BeiGene’s Brukinsa (zanubrutinib) Receives NICE Recommendation for the Treatment of Waldenström’s Macroglobulinemia

Share this

BeiGene’s Brukinsa (zanubrutinib) Receives NICE Recommendation for the Treatment of Waldenström’s Macroglobulinemia

Shots:

  • The NICE has issued a FAD recommending Brukinsa as a new treatment option for routine use in England & Wales to treat WM in adults who have had at least one treatment
  • The company focuses is to achieve affordable access to innovative therapies & plans to work with NICE and the National Health Service in the UK to make the therapies available for blood cancer patients in the UK. Brukinsa has been shown to reduce the growth of malignant B cells in multiple disease-relevant tissues with differing PK from other licensed BTK inhibitors
  • Brukinsa is a BTK inhibitor considered cost-effective in WM & is being evaluated in a broad clinical program as a monothx. & in combination with other therapies for multiple B-cell malignancies

Ref:  Businesswire  Image: BeiGene

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions